drugset / Trial / NCT05528406
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
NaSingle-groupOpen-labelTreatment
Summary
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 (BRAF V600E Inhibitor) in Advanced Solid Tumor With BRAF V600 Mutation
Timeline
- Start
- 2022-10-20
- Primary completion
- 2024-10-30
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX208 | Unknown | 900 mg | Oral |